# R(+)PPX High Dose Treatment of ALS

> **NCT00600873** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bennett, James P., Jr., M.D., Ph.D.** · enrollment: 10 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** R(+) pramipexole dihydrochloride monohydrate

## Key facts

- **NCT ID:** NCT00600873
- **Lead sponsor:** Bennett, James P., Jr., M.D., Ph.D.
- **Sponsor class:** INDIV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2008-09
- **Final completion:** 2009-01
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2010-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00600873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00600873, "R(+)PPX High Dose Treatment of ALS". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00600873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*